Sun Pharmaceutical Industries is trading higher by nearly 1% to Rs 1,101 after the company announced US FDA has granted its subsidiary final approval for its Abbreviated New Drug Applications (ANDA) for generic version of Prandin®, Repaglinide tablets.
Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. These tablets have annual sales of approximately $ 200 million in the US, Sun Pharma said in a release.
Sun Pharma’s subsidiary, being the first-to-file an ANDA for generic Prandin® with a Para IV certification, is eligible for a 180-day marketing exclusivity in the US. The product on a conservative basis will contribute around $30-40 million to the sales of the company in FY2014.
Repaglinide tablets, 1 mg and 2 mg are therapeutic equivalents of Novo Nordisk’s Prandin® tablets, it added.
The stock opened at Rs 1,105 and touched a record high of Rs 1,111 on BSE. A combined around 128,000 shares have changed hands on the counter till 0950 hours on BSE and NSE.
Meanwhile, the pharma stock has outperformed the market by surging 18.2% from its recent low of Rs 940 on June 26, compared to 6.8% rise in benchmark Sensex during the same period.
Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. These tablets have annual sales of approximately $ 200 million in the US, Sun Pharma said in a release.
Sun Pharma’s subsidiary, being the first-to-file an ANDA for generic Prandin® with a Para IV certification, is eligible for a 180-day marketing exclusivity in the US. The product on a conservative basis will contribute around $30-40 million to the sales of the company in FY2014.
Repaglinide tablets, 1 mg and 2 mg are therapeutic equivalents of Novo Nordisk’s Prandin® tablets, it added.
The stock opened at Rs 1,105 and touched a record high of Rs 1,111 on BSE. A combined around 128,000 shares have changed hands on the counter till 0950 hours on BSE and NSE.
Meanwhile, the pharma stock has outperformed the market by surging 18.2% from its recent low of Rs 940 on June 26, compared to 6.8% rise in benchmark Sensex during the same period.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%